Randomized trial · people
Semaglutide: 10.2% weight loss at 208 weeks in SELECT
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a large, long trial, semaglutide's weight loss held for up to 4 years, with fewer serious adverse events than placebo but more people stopping the drug, especially at lower BMI.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 17604
- Published
- 2024
- Journal
- Nat Med
What they tested
The team tested how semaglutide changed weight, body measurements, and safety over time, and whether this differed by starting body mass index (BMI).
How the study was done
A prespecified analysis of a randomized, placebo-controlled trial in 17,604 adults with existing heart or blood vessel disease and overweight or obesity, but no diabetes. Results were compared with placebo, a dummy treatment, over up to 4 years and broken down by BMI group.

Model. Individual results vary.
What they found
In people on semaglutide, weight kept falling through 65 weeks and the loss held for up to 4 years. At 208 weeks, mean weight fell 10.2% with semaglutide versus 1.5% with placebo, waist size fell 7.7 cm versus 1.3 cm, and waist-to-height ratio fell 6.9% versus 1.0% (P < 0.0001 for each). Weight loss judged clinically meaningful was seen in both sexes and across all races, body sizes, and regions. Serious adverse events were less frequent on semaglutide in every BMI group (for example, 47.06 versus 60.85 events per 100 years of observation at a BMI of 40 or more), but more people on semaglutide stopped the study drug, and stopping was more common at lower BMI.
What it doesn’t show
This was a planned side analysis of a trial built mainly to track heart events, and it only included people with existing cardiovascular disease and no diabetes. Results may not apply to people without heart disease or to those with diabetes.
The paper
Ryan et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024.
The compound
More studies on Semaglutide
- Semaglutide: 11.85% more weight loss than placebo without diabetesMeta-analysis · people · 2022
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1Randomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.